<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0001018"><a href="http://purl.obolibrary.org/obo/MONDO_0001018">MONDO:0001018</a></h3>
<p><strong>Label:</strong> lymphoblastic leukemia</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0007243">MONDO:0007243</a> (Burkitts lymphoma), <a href="http://purl.obolibrary.org/obo/MONDO_0004948">MONDO:0004948</a> (chronic lymphocytic leukemia), <a href="http://purl.obolibrary.org/obo/MONDO_0004963">MONDO:0004963</a> (T-cell acute lymphoblastic leukemia), <a href="http://purl.obolibrary.org/obo/MONDO_0020511">MONDO:0020511</a> (precursor b-cell acute lymphoblastic leukemia), <a href="http://purl.obolibrary.org/obo/MONDO_0004967">MONDO:0004967</a> (acute lymphoblastic leukemia (disease)),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_99860">Orphanet:99860</a>, <a href="http://purl.obolibrary.org/obo/OMIM_186770">OMIM:186770</a>, <a href="http://purl.obolibrary.org/obo/OMIM_113970">OMIM:113970</a>, <a href="http://purl.obolibrary.org/obo/OMIM_613065">OMIM:613065</a>, <a href="http://purl.obolibrary.org/obo/OMIM_151400">OMIM:151400</a>, <a href="http://purl.obolibrary.org/obo/OMIM_247640">OMIM:247640</a>, <a href="http://purl.obolibrary.org/obo/OMIM_613067">OMIM:613067</a>, <a href="http://www.orpha.net/ORDO/Orphanet_67038">Orphanet:67038</a>, <a href="http://purl.obolibrary.org/obo/OMIM_615545">OMIM:615545</a>, <a href="http://purl.obolibrary.org/obo/OMIM_612558">OMIM:612558</a>, <a href="http://purl.obolibrary.org/obo/OMIM_612557">OMIM:612557</a>, <a href="http://purl.obolibrary.org/obo/OMIM_609630">OMIM:609630</a>, <a href="http://purl.obolibrary.org/obo/OMIM_612559">OMIM:612559</a>, <a href="http://purl.obolibrary.org/obo/OMIM_109543">OMIM:109543</a>, <a href="http://www.orpha.net/ORDO/Orphanet_543">Orphanet:543</a>, <a href="http://www.orpha.net/ORDO/Orphanet_513">Orphanet:513</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0001626">HP:0001626</a> (Abnormality of the cardiovascular system))) 41.27%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000951">HP:0000951</a> (Abnormality of the skin))) 41.27%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0000707">HP:0000707</a> (Abnormality of the nervous system))) 41.27%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0025031">HP:0025031</a> (Abnormality of the digestive system))) 40.62%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0001894">HP:0001894</a> (Thrombocytosis))) 34.80%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) 33.76%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000005">HP:0000005</a> (Mode of inheritance) and <a href="http://purl.obolibrary.org/obo/HP_0001909">HP:0001909</a> (Leukemia) 33.35%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0004377">HP:0004377</a> (Hematological neoplasm) 33.18%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000005">HP:0000005</a> (Mode of inheritance) and <a href="http://purl.obolibrary.org/obo/HP_0004377">HP:0004377</a> (Hematological neoplasm) 29.65%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002715">HP:0002715</a> (Abnormality of the immune system) and <a href="http://purl.obolibrary.org/obo/HP_0004377">HP:0004377</a> (Hematological neoplasm) 29.60%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0011793">HP:0011793</a> (Neoplasm by anatomical site) 28.47%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002664">HP:0002664</a> (Neoplasm) 28.17%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001871">HP:0001871</a> (Abnormality of blood and blood-forming tissues) 27.32%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010987">HP:0010987</a> (Abnormality of cellular immune system) 26.97%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001881">HP:0001881</a> (Abnormality of leukocytes) 26.97%</li>
</ul>
</body>
</html>
